ZIG
HAE icon

Zullo Investment Group’s Haemonetics HAE Stock Holding History

Zullo Investment Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-90
Closed -$7.08K – 382
2022
Q4 		$7.08K Hold
90
– – ﹤0.01% 542
2022
Q3 		$7K Hold
90
– – ﹤0.01% 538
2022
Q2 		$6K Hold
90
– – ﹤0.01% 581
2022
Q1 		$6K Hold
90
– – ﹤0.01% 619
2021
Q4 		$5K Buy
+90
New +$5.48K ﹤0.01% 654

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zullo Investment Group's HAE Position: Q1 2023 in Review

Zullo Investment Group sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 90 shares — an estimated $7.08K sold.

Zullo Investment Group first reported a position in HAE in Q4 2021 and held it in 5 quarters. The position peaked at $7.08K in Q4 2022. 301 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

  • Zullo Investment Group reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
  • Zullo Investment Group sold 90 Haemonetics shares in Q1 2023, an estimated $7.08K.
  • Zullo Investment Group first reported a position in Haemonetics in Q4 2021 and held it in 5 quarters.
  • Zullo Investment Group's Haemonetics position peaked at $7.08K in Q4 2022.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on Zullo Investment Group's 13F filing for Q1 2023, filed 25 Apr 2023.